Multiple primary cancers in families with Li-Fraumeni syndrome

Journal of the National Cancer Institute

Volumn 90, Issue 8, 1998, Pages 606-611

  Hisada, Michie ^a   Garber, Judy E ^a   Fung, Claire Y ^b   Fraumeni Jr , Joseph F ^c   Li, Frederick P ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; FAMILIAL CANCER; FEMALE; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; POPULATION RISK; STATISTICAL ANALYSIS;

EID: 0032522623     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.8.606     Document Type: Article

References (53)

1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
2. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
3. Lynch HT, Mulcahy GM, Harris RE, Guirgis HA, Lynch JF. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 1978;41:2055-64.
4. Tomlinson MJ, Bullimore JA. Adrenal-cell carcinoma and rhabdomyosarcoma occurring in father and daughter: "SBLA" syndrome? Br J Radiol 1987;60:89-90.
5. Hartley AL, Birch JM, Kelsey AM, Marsden HB, Harris M, Teare MD. Are germ cell tumors part of the Li-Fraumeni cancer family syndrome? Cancer Genet Cytogenet 1989;42: 221-6.
6. Henry I, Grandjouan S, Couillin P, Barichard F, Huerre-Jeanpierre C, Glaser T, et al. Tumor-specific loss of 11p15.5 alleles in de111p13 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sci U S A 1989;86:3247-51.
7. Tsunematsu Y, Watanabe S, Oka T, Tsukamoto T, Kawa-Ha K, Hirata Y, et al. Familial aggregation of cancer from proband cases with childhood adrenal cortical carcinoma. Jpn J Cancer Res 1991;82:893-900.
8. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
9. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J Jr, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995;56:608-15.
10. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993;66:83-92.
11. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 1992;135:190-9.
12. Varley JM, MacGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997;57:3245-52.
13. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:6094-7.
14. Heston J, Kelly J, Meigs J, Flannery J. Forty-five years of cancer incidence in Connecticut: 1935-79. Natl Cancer Inst Monogr 1986;70: 40-637.
15. Ries L, Kosary C, Hankey B, Miller B, Harras A, Edwards B, editors. SEER cancer statistics review, 1973-1994. NIH Publ No. 97-2789. Bethesda (MD): National Cancer Institute, 1997.
16. Monson RR. Analysis of relative survival and proportional mortality. Comput Biomed Res 1974;7:325-32.
17. Dean CB. Testing of overdispersion in Poisson and binomial regression models. J Am Stat Assoc 1992;87:451-7.
18. McCullagh P, Nelder JA. Log-linear models. In: McCullagh P, Nelder JA, editors. Generalized linear models. 2nd ed. London: Chapman & Hall, 1989:200-44.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;457-81.
20. Mantel N, Ciminera JL. Use of logrank scores in the analysis of litter-matched data on time to tumor appearance. Cancer Res 1979;39: 4308-15.
21. Cohen RJ, Wiernik PH, Walker MD. Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: report of two cases. Cancer Treat Rep 1976;60:1257-61.
22. Vogl SE. Acute leukemia complicating treatment of glioblastoma multiforme. Cancer 1978;41: 333-6.
23. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85: 1121-8.
24. Mulligan LH, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363: 458-60.
25. Hamilton SR, Liu B, Parsons RE, Papdopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332: 839-47.
26. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
27. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
28. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351: 453-6.
29. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-52.
30. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326: 1301-8.
31. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992;326: 1309-15.
32. Varley JM, Thorncroft M, McGown G, Tricker K, Birch JM, Evans DG. A novel deletion within exon 6 of TP53 in a family with Li-Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genet Cytogenet 1996;90:14-6.
33. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 1997;76:1-14.
34. Cornelis RS, van Vliet M, van de Vijver MJ, Vasen HF, Voute PA, Top B, et al. Three gemiline mutations in the TP53 gene. Hum Mutat 1997;9:157-63.
35. Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. Br J Cancer 1987;55:179-90.
36. National Research Council. Health effects of exposure to low levels of ionizing radiation (BEIR V). Washington (DC): National Academy Press, 1990.
37. Taghian A, de Vathaire F, Terrier P, Le M, Auquier A, Mouriesse H, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991;21:361-7.
38. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326:781-5.
39. Travis LB, Curtis RE, Boice JD Jr, Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996;56:1564-70.
40. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-25.
41. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-7.
42. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348: 747-9.
43. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 1994;8: 66-9.
44. Lee JM, Abrahamson JL, Kandel R, Donehower LA, Bernstein A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 1994;9:3731-6.
45. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31.
46. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897-904.
47. Li FP. Identification and management of inherited cancer susceptibility. Environ Health Perspect 1995;103 Suppl 8:297-300.
48. Leitch AM. Controversies in breast cancer screening. Cancer 1995;76(10 Suppl):2064-9.
49. Mettlin C, Murphy GP. Breast cancer screening in premenopausal women: current recommendations and opportunities for research. Ann Med 1995;27:461-5.
50. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71.
51. Eng C, Schneider K, Fraumeni JF Jr, Li FP. Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev 1997;6: 379-83.
52. Baker SG, Freedman LS. Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. J Natl Cancer Inst 1995;87:1137-44.
53. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res 1995;55:3949-53.